Table 2. The results of subgroup analyses.
| Variables | N | SEN (95% CI), I2 (%) | SPE (95% CI), I2 (%) | PLR (95% CI), I2 (%) | NLR (95% CI), I2 (%) | DOR (95% CI), I2 (%) |
|---|---|---|---|---|---|---|
| Publication year | ||||||
| Before 1999 | 17 | 0.79 (0.72−0.85), 0 | 0.82 (0.78−0.86), 53.1 | 3.66 (2.88−4.64), 0 | 0.37 (0.26−0.53), 28.8 | 13.79 (8.37−22.72), 0 |
| After 2000 | 19 | 0.84 (0.81−0.88), 76.1 | 0.68 (0.65−0.72), 68.0 | 2.23 (1.80−2.76), 46.8 | 0.35 (0.22−0.58), 80.1 | 7.91 (4.18−14.98), 58.6 |
| Geographic location | ||||||
| Asia and Africa | 23 | 0.85 (0.82−0.88), 63.9 | 0.70 (0.66−0.73), 67.6 | 2.57 (2.09−3.15), 54.0 | 0.31 (0.22−0.44), 60.3 | 10.47 (6.32−17.34), 46.8 |
| Europe and America | 13 | 0.66 (0.53−0.77), 40.5 | 0.83 (0.78−0.86), 58.2 | 3.07 (2.02−4.66), 14.8 | 0.54 (0.349−0.82), 48.8 | 8.01 (3.50−18.35), 24.5 |
| Sample size (n, mean) | ||||||
| ≥ 46 | 10 | 0.85 (0.81−0.88), 83.5 | 0.72 (0.68−0.75), 82.3 | 2.60 (1.94−3.48), 69.8 | 0.31 (0.17−0.57), 85.4 | 10.41 (4.97−21.81), 67.9 |
| < 46 | 26 | 0.79 (0.72−0.85), 31.2 | 0.77 (0.73−0.81), 60.5 | 2.70 (2.12−3.44), 24.1 | 0.41 (0.29−0.58), 43.8 | 9.10 (5.39−15.34), 15.9 |
| IHC antibodies | ||||||
| DO-7 antibody | 17 | 0.73 (0.66−0.79), 58.1 | 0.71 (0.67−0.75), 69.0 | 2.27 (1.73−2.99), 47.2 | 0.46 (0.32−0.67), 61.2 | 6.48 (3.53−11.88), 39.0 |
| DO-1 antibody | 4 | 0.80 (0.73−0.89), 0 | 0.84 (0.77−0.89), 0 | 4.74 (3.21−7.01), 0 | 0.26 (0.16−0.43), 0 | 19.75 (8.98−43.42), 0 |
| CM-1 antibody | 4 | 0.71 (0.54−0.85), 17.1 | 0.59 (0.46−0.71), 0 | 1.71 (1.21−2.43), 0 | 0.58 (0.34−0.99), 10.0 | 3.69 (1.46−9.34), 0 |
| PAb1801 antibody | 4 | 0.80 (0.52−0.96), 0 | 0.91 (0.82−0.97), 79.4 | 8.54 (1.82−40.14), 60.3 | 0.34 (0.15−0.75), 0 | 30.79 (6.58−144.13), 0 |
| Mutational assays | ||||||
| All DNA sequencing | 21 | 0.89 (0.85−0.92), 57.3 | 0.70 (0.66−0.74), 75.2 | 2.43 (1.93−3.06), 39.9 | 0.32 (0.19−0.55), 73.6 | 11.10 (5.96−20.68), 36.8 |
| Partial DNA sequencing | 15 | 0.72 (0.65−0.77), 39.4 | 0.78 (0.74−0.81), 53.4 | 2.80 (2.09−3.77), 51.5 | 0.43 (0.31−0.59), 54.5 | 7.81 (4.32−14.10), 49.3 |
| Prevalence of p53 alterations | ||||||
| Mutation ≥ 35% | 15 | 0.85 (0.82−0.88), 71.2 | 0.67 (0.64−0.73), 50.0 | 2.41 (1.92−3.03), 37.0 | 0.30 (0.20−0.47), 66.7 | 9.74 (5.18−18.33), 56.4 |
| Mutation < 35% | 21 | 0.76 (0.68−0.83), 48.0 | 0.77 (0.74−0.80), 75.0 | 2.94 (2.15−4.04), 54.2 | 0.43 (0.28−0.66), 61.3 | 9.91 (5.40−18.18), 25.5 |
| Overexpression ≥ 46% | 18 | 0.87 (0.83−0.90), 63.1 | 0.64 (0.59−0.68), 32.8 | 2.21 (1.84−2.65), 33.0 | 0.29 (0.19−0.45), 60.1 | 8.82 (4.97−15.67), 47.3 |
| Overexpression < 46% | 18 | 0.71 (0.62−0.78), 42.1 | 0.83 (0.79−0.86), 58.3 | 3.71 (2.70−5.11), 27.9 | 0.46 (0.31−0.68), 62.3 | 11.21 (5.63−22.29), 36.8 |
SEN, sensitivity; SPE, specificity; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; CI, confidence interval.